I had the new IBS test last Tuesday and got the results back today. The test is called ibschek.
Reports suggest that elevated anti-CdtB and anti-Vinculin antibody levels are more commonly found in patients with diarrhea predominant irritable bowel syndrome than in healthy controls. These same reports found that patients with other bowel diseases also may have elevated levels of anti-CdtB and anti Vinculin. Patients with celiac disease, in particular, were found to have elevated levels of both antibodies. Moreover, a positive anti-CdtB and/or anti-Vinculin antibody does not exclude inflammatory bowel disease.
This test was developed and it’s analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by the FDA. It has been validated pursuant to the CLIA regulations and is used for clinical purposes.
I wanted to explain the test and how they determine the outcome.
My test came back as follows: one or both IBSDetex (TM) results are above the 95th percentile for a reference group of healthy adult people.
Vinculin Antibody Result 1.92 Range OR 1.00
CYTOLETHAL DISTRNDING TOXIN B AB Result 0.31 Range OR 1.00
Result: patient results are 95 percent consistent with the diagnosis of Irritable Bowel Syndrome (IBS). Progress forward with diagnosis positive.